Literature DB >> 7680132

Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase.

J M Nuss1, P B Whitaker, G M Air.   

Abstract

We have examined amino acids on influenza virus neuraminidase (NA) subtype N9 (A/tern/Australia/G70c/75) which are in contact with monoclonal antibody NC41 to analyze individual interactions important for antibody recognition. The crystal structure of NA complexed with NC41 Fab1 shows antibody contacts at 19 amino acid residues on the NA surface which are localized on five polypeptide loops surrounding the enzyme active site. Fifteen mutant NA genes were constructed to encode a protein which contained a single amino acid substitution and these were tested for effects of the replacement on NC41 binding. Our data revealed that NAs with changes at 368, 400, and 434 completely lost NC41 recognition. NAs with side chains replaced at residues 346 and 373 exhibited binding reduced to less than 50% of wild-type binding. Changes in seven other contacting residues, including substituted side chains which differed considerably from wild-type NA in size and charge, had no significant effect on NC41 binding. These results indicate that only a few of the many residues which make up an epitope are crucial for interaction and provide the critical contacts required for antibody recognition. This implies that antibody escape mutants are selected only if they contain changes at these crucial sites, or changes which introduce bulky side chains that sterically prevent antibody attachment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680132     DOI: 10.1002/prot.340150204

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  9 in total

1.  Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).

Authors:  Upma Gulati; Chi-Ching Hwang; Lalitha Venkatramani; Shelly Gulati; Stephen J Stray; Janis T Lee; W Graeme Laver; Alexey Bochkarev; Adam Zlotnick; Gillian M Air
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Directed mutagenesis identifies amino acid residues involved in elongation factor Tu binding to yeast Phe-tRNAPhe.

Authors:  Lee E Sanderson; Olke C Uhlenbeck
Journal:  J Mol Biol       Date:  2007-02-06       Impact factor: 5.469

3.  Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase.

Authors:  T Saito; G Taylor; W G Laver; Y Kawaoka; R G Webster
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

4.  "Boom" and "Bust" cycles in virus growth suggest multiple selective forces in influenza a evolution.

Authors:  Rajagowthamee R Thangavel; Aisha Reed; Erin W Norcross; Sherrina N Dixon; Mary E Marquart; Stephen J Stray
Journal:  Virol J       Date:  2011-04-18       Impact factor: 4.099

Review 5.  Influenza neuraminidase.

Authors:  Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2011-11-16       Impact factor: 4.380

6.  Monoclonal antibodies targeting the influenza virus N6 neuraminidase.

Authors:  Shirin Strohmeier; Fatima Amanat; Juan Manuel Carreño; Florian Krammer
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

7.  Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin.

Authors:  Stephen J Stray; Lindsey B Pittman
Journal:  Virol J       Date:  2012-05-08       Impact factor: 4.099

Review 8.  NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Authors:  Florian Krammer; Ron A M Fouchier; Maryna C Eichelberger; Richard J Webby; Kathryn Shaw-Saliba; Hongquan Wan; Patrick C Wilson; Richard W Compans; Ioanna Skountzou; Arnold S Monto
Journal:  mBio       Date:  2018-04-03       Impact factor: 7.867

Review 9.  Epitope mapping: the first step in developing epitope-based vaccines.

Authors:  Jonathan M Gershoni; Anna Roitburd-Berman; Dror D Siman-Tov; Natalia Tarnovitski Freund; Yael Weiss
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.